AbbVie Inc. (ABBV) Q2 2026 Earnings Name July 31, 2026 9:00 AM EDT
Firm Members
Elizabeth Shea – Senior Vice President of Investor Relations
Robert Michael – CEO & Chairman of the Board
Jeffrey Stewart – Government VP & Chief Industrial Officer
Roopal Thakkar – Government VP of Analysis & Growth and Chief Scientific Officer
Scott Reents – Government VP & CFO
Convention Name Members
Terence Flynn – Morgan Stanley, Analysis Division
Carter Gould – Cantor Fitzgerald & Co., Analysis Division
Christopher Schott – JPMorgan Chase & Co, Analysis Division
Michael Yee – UBS Funding Financial institution, Analysis Division
Mohit Bansal – Wells Fargo Securities, LLC, Analysis Division
Asad Haider – Goldman Sachs Group, Inc., Analysis Division
David Amsellem – Piper Sandler & Co., Analysis Division
Luisa Hector – Joh. Berenberg, Gossler & Co. KG, Analysis Division
Matthew Phipps – William Blair & Firm L.L.C., Analysis Division
Louise Chen – Scotiabank World Banking and Markets, Analysis Division
Evan Seigerman – BMO Capital Markets Fairness Analysis
Presentation
Operator
Good morning, and thanks for standing by. Welcome to the AbbVie Second Quarter 2026 Earnings Convention Name. [Operator Instructions] At this time’s name can be being recorded. If in case you have any objections, you might disconnect at the moment. I might now wish to introduce Ms. Liz Shea, Senior Vice President, Investor Relations.
Elizabeth Shea
Senior Vice President of Investor Relations
Good morning, and thanks for becoming a member of us. Additionally on the decision with me at this time are Rob Michael, Chairman and Chief Government Officer; Jeff Stewart, Government Vice President, Chief Industrial Officer; Roopal Thakkar, Government Vice President, Analysis and Growth, Chief Scientific Officer; and Scott Reents, Government Vice President, Chief Monetary Officer.
Earlier than we get began, I am going to observe that some statements we make at this time could also be thought-about forward-looking statements primarily based on our present expectations. AbbVie cautions that these forward-looking statements are topic to dangers and uncertainties that will trigger precise outcomes
